Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Bristol-Myers Squibb Company F4Q08 and Full Year Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions Your first question comes from John Boris with Citigroup. John Boris - Citigroup My first question is for Elliott. Yesterday there was an early communication from the FDA on a safety review on clopidagril, most notably on patients that...
- Earnings calls 2009-01-27
- Bristol-Myers Squibb Company Q1 2009 Earnings Call Transcript
- Question-and-Answer Session Operator Operator Instructions Your first question comes from Tony Butler - Barclays Capital. Tony Butler - Barclays Capital Two questions; one is Plavix internationally in the areas in which you marketed continues to decline fairly precipitously. Is this again principally due to Germany or...
- Earnings calls 2009-04-28
- Bristol-Myers Squibb Company Q2 2009 Earnings Call Transcript
- Question-and-Answer SessionOperator Thank you. Operator instructions Our first question comes from Mr. Jami Rubin with Goldman Sachs. Jami Rubin - Goldman Sachs Hi. Mrs. Jami Rubin. Anyway, very good quarter. I wanted to ask you Jim as long as we have you on the call to talk sort of...
- Earnings calls 2009-07-23
- The Sanofi-Bristol-Myers Squibb Worst-Case Scenario
- Bristol-Myers Squibb seems to live permanently with the rumor that it is about to be acquired by Sanofi-Aventis. The last time this old saw popped up was in the fall of 2008. At that time BNET said "Perhaps it’s time to consummate this relationship." This time around,...
- Blog posts 2009-02-03
- BMS Settles Plavix Allegations for Pennies; Ex-CEO Dolan Vindicated (Slightly)
- Bristol-Myers Squibb will pay $2.1 million to settle FTC allegations it made false statements regarding its deal over bloodthinner Plavix with Apotex, according to the WSJ. The news means that BMS has settled all its regulatory troubles over Plavix with the FTC and the states for a...
- Blog posts 2009-03-27
- BMS's Bodnar Caught in His Own Lies on Apotex-Plavix Deal
- Former Bristol-Myers Squibb svp/strategy Andrew Bodnar faces a year in prison after he pled guilty to lying to the FTC about BMS's generic deal with Apotex. The conviction carries a lesson for senior drug company executives hoping to put one over on the government: If you're going...
- Blog posts 2009-04-07
Additional Resources
- Astra Drug Beats Plavix in Prevention
- By Ben Hirschler BARCELONA (Reuters UK) - AstraZeneca's AZN new pill Brilinta for preventing heart attacks works better than Plavix, the world's second biggest selling drug, without increasing the amount of life-threatening bleeding, researchers said on Sunday. The positive clinical trial result should ensure the blood thinner wins a slice...
- News items 2009-08-31
- Study: Plavix ads boosted prices, not sales
- Does pharma's consumer advertising increase sales--or just prices? A new study in the Archives of Internal Medicine found that at least for Plavix, the blockbuster blood thinner marketed by Bristol-Myers Squibb and Sanofi-Aventis, a big advertising campaign didn't do much to boost prescriptions. But Plavix prices increased immediately, researchers found. That's...
- News items 2009-11-24
- Generic Plavix version blocked by U.S. District Court
- A Canadian company's cheap generic version of the blood thinner Plavix has been blocked from the U.S. market until at least 2011. U.S. District Judge Sidney H. Stein said Tuesday that Apotex Inc. had failed to prove during a three-week trial in New York City earlier this year that the...
- Research articles 2007-06-21
- FDA cites Sanofi-Synthelabo on Plavix promo
- > The FDA has told Sanofi-Synthelabo to stop using a visual sales aid for its antiplatelet drug Plavix clopidogrel bisulfate because it overstated the efficacy of the drug, according to a just-released May 8 notice-of-violation letter. The aid is misleading, wrote Division of Drug Marketing, Advertising, and Communications reviewer Andrew...
- Research articles 2001-07-01
- Bristol-Myers Squibb initiates pitch for Plavix following Ogilvy's resignation
- BRISTOL-MYERS Squibb has begun a review for the $70 million account of the prescription blood-thinning drug Plavix. The account was with WPP Group's Ogilvy & Mather. An Ogilvy spokeswoman confirmed that the agency resigned the account in December after holding it for more than four years. Bristol-Myers Squibb, which co-markets...
- Research articles 2004-03-01
- Kroner suit aims to overturn deal on generic form of Plavix
- CINCINNATI -- Kroger Co. has gone to court to block a deal that would delay generic alternatives to the popular blood-thinning drug Plavix. Bristol-Myers Squibb Co. and Sanofi-Aventis had reached a settlement with generic drug maker Apotex Inc. over a patent dispute regarding Plavix, which is the world's No....
- Research articles 2006-04-24
- Late News; O&M resigns Rx Plavix; $70 mil acc't in review.(briefs)
- [New York] Bristol-Myers Squibb Co. put the advertising assignment for prescription blood-thinning medication Plavix into review after parting ways with WPP Group's Ogilvy & Mather, New York, executives close to the situation said. An Ogilvy spok [New York] Bristol-Myers Squibb Co. put the advertising assignment ...
- Research articles 2004-01-26
- The Week; Saatchi wins $70M Plavix acc't.(Briefs)
- Bristol-Myers Squibb and Sanofi-Synthelabo, co-marketers of Plavix, awarded the $70 million account to Publicis Groupe's Saatchi & Saatchi Healthcare, a Bristol-Myers spokesman confirmed. The prescription blood-thinning medication is the market l Bristol-Myers Squibb and Sanofi-Synthelabo, co-marketers of Plavix, awarded the $70 million account to Publicis...
- Research articles 2004-03-29
- Bristol-Myers Squibb plans fall campaign for Plavix; Ad pushes drug preventing stroke and heart attacks.(Brief Article)
- After a false start, Bristol-Myers Squibb Co. is ready to launch the first direct-to-consumer advertising for Plavix, its prescription heart attack and stroke prevention drug. After a false start, Bristol-Myers Squibb Co. is ready to launch the first direct-to-consumer advertising for Plavix, its prescription...
- Research articles 2000-06-26
- Apotex Announces Agreement to Settle U.S. PLAVIX® Litigation; Apotex Announces Agreement to Settle U.S. Plavix® Litigation with Sanofi-aventis and Bristol-Myers Squibb Subject to Certain Conditions
- WESTON, Fla. -- Apotex Inc. and Apotex Corp. announced today that they have reached an agreement with Sanofi-aventis and Bristol-Myers Squibb, subject to certain conditions, to settle the patent infringement lawsuit pending between the parties in the U.S. District Court for the Southern District of New York. The lawsuit relates...
- Research articles 2006-03-22
- Canadian drugmaker asks court to approve generic Plavix
- NEW YORK AFP — Lawyers for a Canadian generic drugmaker asked a US court to lift an injunction barring the sale of its version of the blockbuster heart drug Plavix, arguing that the patent is invalid. The arguments came in a federal court trial over the rights for Plavix, a...
- Research articles 2007-01-22
- US court upholds patent for heart drug Plavix
- NEW YORK AFP — A US judge on Tuesday upheld the patent for Plavix by French group Sanofi-Aventis and its US partner Bristol-Myers Squibb, blocking a generic version of the blockbuster heart drug. The ruling by US District Judge Sidney Stein bars Canadian firm Apotex from producing a generic...
- Research articles 2007-06-19
- Bristol-Myers Squibb, Makers of Plavix, Face Injury Lawsuits Filed by Hersh & Hersh and Miller & Associates
- Plavix Patients' Lawsuit Comes on Heels of Class Action Suit Announced by Third-Party Payors Last Week
- Research articles 2006-10-31
- Prasugrel better on stent-related clots than Plavix: study
- CHICAGO, March 29, 2008 AFP — A cocktail of new anti-blood clot drug Prasugrel and aspirin reduces the risk of stent-related clots more than the standard treatment, according to a clinical trial review presented Saturday. Prasugrel cut the risk of platelet formation around where a stent -- a small...
- Research articles 2008-03-29
- << Previous
- page 1 of 1
- Next >>
